1684393-04-1

Rosmantuzumab (25 mg/kg; i.p., once a week for 4 weeks) significantly protects the animals from developing liver fibrosis^[1]. Rosmantuzumab (25 mg/kg; i.p., once for two weeks, for total 6 weeks) significantly inhibits skin thickness, collagen deposition, and number of α-SMA positive cells in bleomycin-induced lung fibrosis mouse models^[1].